Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

• Sponsor: Millennium Pharmaceuticals, Inc. (Industry)
• Overall Status: Completed
• CT.gov ID: NCT04454918
• Collaborator: (none)
• Enrollment: 6
• Location: 1
• Arm: 1
• Actual Duration (Months): 2
• Patients Per Site Per Month: 2.9

Study Details

Study Description

Brief Summary

The purpose of this study is to determine ABA of TAK-906 following single oral (capsule) administration of 50 milligram (mg) of TAK-906 and single intravenous (IV) microtracer dose administration of 100 microgram (μg) (approximately 1 microcurie [μCi]) of [14C]-TAK-906 in Period 1 (ABA), and to determine the mass balance of TAK-906 in urine and feces following a single oral (solution) administration of 50 mg (approximately 100 μCi) of [14C]-TAK-906 in Period 2 (absorption, distribution, metabolism, and elimination [ADME]).

Condition or Disease	Intervention/Treatment	Phase
Healthy Volunteers	Drug: TAK-906 Oral Capsule; Drug: [14C]-TAK-906 Intravenous Infusion; Drug: [14C]-TAK-906 Oral Solution	Phase 1

Detailed Description

The drug being tested in this study is called TAK-906. The study will determine ABA in Period 1, and ADME, and mass balance of TAK-906 after single oral administration in Period 2 in healthy adult male participants. Plasma and urine samples will be collected for PK determination; plasma, whole blood, urine, and feces samples will be collected for total radioactivity (TRA) determination; and plasma, urine, and feces samples will be collected to characterize the metabolite profiles of TAK-906.

The study will enroll approximately 6 participants. The study is designed to consist of 2 periods: Period 1 (ABA study period) and Period 2 (ADME study period). In Period 1 (ABA study period), all participants will receive single unlabeled oral 50 mg dose of TAK-906 as capsule followed by microdose of 100 μg (approximately 1 μCi) [14C]-TAK-906 as intravenous infusion followed by a washout period of at least 7 days before the dose in Period 2. In Period 2 (ADME study period), all participants will receive a single dose of 50 mg (approximately 100 μCi) [14C]-TAK-906 as an oral solution.

This single center trial will be conducted in the United States. The overall time to participate in this study is approximately 65 days including screening period. Participants will be contacted approximately 30 days after the last dose of study drug for a follow-up assessment.

Study Design

• Study Type: Interventional
• Actual Enrollment: 6 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: A Phase 1 Study to Assess Absolute Bioavailability of TAK-906 and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Subjects
• Actual Study Start Date: Jul 30, 2020
• Actual Primary Completion Date: Sep 30, 2020
• Actual Study Completion Date: Sep 30, 2020

Arms and Interventions

Arm

Intervention/Treatment

Experimental: TAK-906 50 mg + [14C]-TAK-906 100 mcg + [14C]-TAK-906 50 mg TAK-906 50 mg, capsule, orally, once on Day 1, followed by [14C]-TAK-906 100 micrograms (μg) [approximately 1 microcurie (μCi)], IV infusion, once on Day 1 of Treatment Period 1, followed by a Washout Period of 7 days, further followed by [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.

Drug: TAK-906 Oral Capsule; TAK-906 capsule.; Drug: [14C]-TAK-906 Intravenous Infusion; [14C]-TAK-906 intravenous infusion.; Drug: [14C]-TAK-906 Oral Solution; [14C]-TAK-906 oral solution.

Outcome Measures

Primary Outcome Measures

1. Period 1: Absolute Bioavailability Based on Ratio of Dose Normalized Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞ ) for TAK-906 [Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1]

   Bioavailability is defined as the proportion of a drug which enters the circulation when introduced into the body and so is able to have an active effect. Percent absolute bioavailability for plasma TAK-906, calculated as geometric least squares mean ratio: [Actual Dose (IV) x AUC∞ (oral)] / [Actual Dose (oral) x AUC∞ (IV)] multiplied (x) 100, where AUC∞ for IV infusion was normalized to a 50 mg dose.

2. Period 2: Cum%Dose (UR): Cumulative Percentage of Total Radioactivity Excreted in Urine for [14C]-TAK-906 [Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2]

3. Period 2: Cum%Dose (FE): Cumulative Percentage of Total Radioactivity Excreted in Feces for [14C]-TAK-906 [Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2]

4. Period 2: Combined Cum%Dose: Cumulative Combined Percent of Total Radioactivity Excreted in Urine and Feces for [14C]-TAK-906 [Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2]

Secondary Outcome Measures

1. Period 1: Cmax: Maximum Observed Plasma Concentration for TAK-906 and Metabolite (M23) After Oral Administration [Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1]

2. Period 1: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 and M23 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1]

3. Period 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906 and M23 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1]

4. Period 1: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for TAK-906 and M23 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1]

5. Period 1: t(1/2)z : Terminal Disposition Phase Half-life for TAK-906 and M23 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1]

6. Period 1: Vz/F: Apparent Volume of Distribution During the Terminal Elimination Phase for TAK-906 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1]

7. Period 1: CL/F: Apparent Total Plasma Clearance for TAK-906 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1]

8. Period 1: Ceoi: Plasma Total Radioactivity Concentration at the End of Infusion for [14C]-TAK-906 [Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1]

9. Period 1: AUClast: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 [Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1]

10. Period 1: AUC∞: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906 [Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1]

11. Period 1: t(1/2)z: Terminal Disposition Phase Half-life of Plasma Total Radioactivity Concentration for [14C]-TAK-906 [Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1]

12. Period 1: Ceoi: Plasma Concentration at the End of Infusion for [14C]-TAK-906 [Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1]

13. Period 1: CL: Total Clearance for [14C]-TAK-906 [Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1]

14. Period 1: Vss: Volume of Distribution During the Terminal Disposition Phase for [14C]-TAK-906 [Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1]

15. Period 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 [Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1]

16. Period 1: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for [14C]-TAK-906 [Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1]

17. Period 1: t(1/2)z: Terminal Disposition Phase Half-life for [14C]-TAK-906 [Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1]

18. Period 2: Cmax: Maximum Observed Plasma Concentration for TAK-906 and M23 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2]

19. Period 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 and M23 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2]

20. Period 2: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906 and M23 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2]

21. Period 2: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-906 and M23 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2]

22. Period 2: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for TAK-906 and M23 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2]

23. Period 2: t(1/2)z: Terminal Disposition Phase Half-life for TAK-906 and M23 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2]

24. Period 2: Vz/F: Apparent Volume of Distribution During the Terminal Elimination Phase for TAK-906 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2]

25. Period 2: CL/F: Apparent Total Plasma Clearance for TAK-906 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2]

26. Period 2: Cmax: Maximum Observed Plasma Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2]

27. Period 2: Tmax: Time to Reach the Maximum Plasma Total Radioactivity Concentration (Cmax) for [14C]-TAK-906 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2]

28. Period 2: AUCt: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Time of the Last Common Time Point t for [14C]-TAK-906 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2]

29. Period 2: AUClast: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2]

30. Period 2: AUC∞: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2]

31. Period 2: t(1/2)z: Terminal Disposition Phase Half-life of Plasma Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2]

32. Period 2: Cmax: Maximum Observed Whole Blood Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2]

33. Period 2: Tmax: Time to Reach the Maximum Whole Blood Total Radioactivity Concentration (Cmax) for [14C]-TAK-906 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2]

34. Period 2: AUClast: Area Under the Whole Blood Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2]

35. Period 2: AUC∞: Area Under the Whole Blood Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2]

36. Period 2: t(1/2)z: Terminal Disposition Phase Half-life of Whole Blood Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration [Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 19 Years to 55 Years
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

1. Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dosing and throughout the study.

2. Body mass index (BMI) greater than or equal to (>=) 18.0 and less than (˂) 30.0 kilogram per square meter (kg/m^2) at screening.

Exclusion Criteria:

1. QT interval corrected for heart rate using Fridericia's formula (QTcF) interval is greater than (>) 450 millisecond (msec) or Electrocardiogram (ECG) findings are deemed abnormal with clinical significance by the Investigator or designee at screening.

2. Estimated creatinine clearance less than (<) 90 milliliter per minute (mL/min) at screening.

3. Has tattoo(s) or scarring at or near the site of intravenous (IV) infusion or any other condition which may interfere with infusion site examination, in the opinion of the Investigator.

4. Has infrequent bowel movements (less than approximately once per day) within 30 days prior to first dosing.

5. Has received radiolabeled substances or has been exposed to radiation sources within 12 months of first dosing or is likely to receive radiation exposure or radioisotopes within 12 months of last dosing such that participation in this study would increase their total exposure beyond the recommended levels considered safe (that is weighted annual limit recommended by the International Commission on Radiological Protection [ICRP] of 3000 milli roentgen equivalent man [mrem]).

6. Has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or designee, within the 30 days prior to the first dosing and throughout the study.

7. Donation of blood or significant blood loss within 56 days prior to the first dosing.

8. Plasma donation within 7 days prior to the first dosing.

9. Unable to refrain from or anticipates the use of:

• Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements within 14 days prior to the first dosing and throughout the study. Acetaminophen (up to 2 g per 24 hour period) and Milk of Magnesia® (that is, magnesium hydroxide [less than or equal to (<=) 60 mL per day after Day 3 in Period 1 and after Day 8 in Period 2]) may be permitted during the study, only after dosing, if necessary to treat adverse events (AEs). Additional administration of Milk of Magnesia® may be administered on other days at discretion of the Investigator.

• Any drugs known to significantly affect the absorption, distribution, metabolism or elimination of TAK-906 within 28 days prior to the first dosing and throughout the study. Appropriate sources (example, Flockhart Table TM) will be consulted to confirm lack of PK/pharmacodynamics interaction with study drug.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Celerion	Lincoln	Nebraska	United States	68502

Sponsors and Collaborators

• Millennium Pharmaceuticals, Inc.

Investigators

• Study Director: Medical Director, Millennium Pharmaceuticals, Inc.

Study Documents (Full-Text)

• Study Protocol - Mar 30, 2020
• Statistical Analysis Plan - Aug 10, 2020

More Information

Publications

None provided.

• Responsible Party: Millennium Pharmaceuticals, Inc.
• ClinicalTrials.gov Identifier: NCT04454918
• Other Study ID Numbers: TAK-906-1007; U1111-1254-4588
• First Posted: Jul 2, 2020
• Last Update Posted: Mar 7, 2022
• Last Verified: Dec 1, 2021

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Millennium Pharmaceuticals, Inc.: Drug Therapy

Study Results

Participant Flow

Recruitment Details	Participants took part in the study at 1 investigative site in the United States from 30 July 2020 to 29 September 2020.
Pre-assignment Detail	Healthy male participants were enrolled in this study to receive TAK-906 capsule followed by radio-labelled TAK-906 intravenous (IV) infusion on Day 1 of Treatment Period 1 and radio-labelled TAK-906 oral solution on Day 1 of Treatment Period 2. There was a 7-day Washout Period between the two periods.

Arm/Group Title	TAK-906 50 mg + [14C]-TAK-906 100 μg + [14C]-TAK-906 50 mg
Arm/Group Description	TAK-906 50 mg, capsule, orally, once on Day 1, followed by [14C]-TAK-906 100 micrograms (μg) [approximately 1 microcurie (μCi)], IV infusion, once on Day 1 of Treatment Period 1, followed by a Washout Period of 7 days, further followed by [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Period Title: Treatment Period 1 (Day 1)
STARTED	6
COMPLETED	6
NOT COMPLETED	0
Period Title: Treatment Period 1 (Day 1)
STARTED	6
COMPLETED	6
NOT COMPLETED	0
Period Title: Treatment Period 1 (Day 1)
STARTED	6
COMPLETED	6
NOT COMPLETED	0

Baseline Characteristics

Arm/Group Title	TAK-906 50 mg + [14C]-TAK-906 100 μg + [14C]-TAK-906 50 mg
Arm/Group Description	TAK-906 50 mg, capsule, orally, once on Day 1, followed by [14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, followed by a Washout Period of 7 days, further followed by [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Overall Participants	6
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	36.7 (8.04)
Sex: Female, Male (Count of Participants)
Female	0 0%
Male	6 100%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%
Not Hispanic or Latino	6 100%
Unknown or Not Reported	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%
Asian	0 0%
Native Hawaiian or Other Pacific Islander	0 0%
Black or African American	1 16.7%
White	5 83.3%
More than one race	0 0%
Unknown or Not Reported	0 0%
Region of Enrollment (Count of Participants)
United States	6 100%
Weight (kg) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [kg]	87.30 (13.242)
Height (cm) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [cm]	181.7 (8.19)
Body Mass Index (BMI) (kg/m^2) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [kg/m^2]	26.408 (2.9179)

Outcome Measures

1. Primary Outcome

Title	Period 1: Absolute Bioavailability Based on Ratio of Dose Normalized Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞ ) for TAK-906
Description	Bioavailability is defined as the proportion of a drug which enters the circulation when introduced into the body and so is able to have an active effect. Percent absolute bioavailability for plasma TAK-906, calculated as geometric least squares mean ratio: [Actual Dose (IV) x AUC∞ (oral)] / [Actual Dose (oral) x AUC∞ (IV)] multiplied (x) 100, where AUC∞ for IV infusion was normalized to a 50 mg dose.
Time Frame	Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

Pharmacokinetic (PK) Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules followed by [14C]-TAK-906 100 μg [approximately 1 μCi], IV infusion in Period 1 were evaluated for this outcome measure.

Arm/Group Title	TAK-906 50 mg + [14C]-TAK-906 100 μg
Arm/Group Description	TAK-906 50 mg, capsule, orally, once on Day 1, followed by [14C]-TAK-906 100 μg [approximately 1 μCi], IV infusion, once on Day 1 of Treatment Period 1.
Measure Participants	6
Geometric Least Squares Mean (90% Confidence Interval) [percent absolute bioavailability]	9.12

2. Primary Outcome

Title	Period 2: Cum%Dose (UR): Cumulative Percentage of Total Radioactivity Excreted in Urine for [14C]-TAK-906
Time Frame	Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [percentage of dose]	2.162 (21.8)

3. Primary Outcome

Title	Period 2: Cum%Dose (FE): Cumulative Percentage of Total Radioactivity Excreted in Feces for [14C]-TAK-906
Time Frame	Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [percentage of dose]	94.44 (1.9)

4. Primary Outcome

Title	Period 2: Combined Cum%Dose: Cumulative Combined Percent of Total Radioactivity Excreted in Urine and Feces for [14C]-TAK-906
Time Frame	Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [percentage of dose]	96.65 (1.7)

5. Secondary Outcome

Title	Period 1: Cmax: Maximum Observed Plasma Concentration for TAK-906 and Metabolite (M23) After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure.

Arm/Group Title	TAK-906 50 mg
Arm/Group Description	TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1.
Measure Participants	6
TAK-906	29.72 (49.2)
Metabolite (M23)	2.293 (50.4)

6. Secondary Outcome

Title	Period 1: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 and M23 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure.

Arm/Group Title	TAK-906 50 mg
Arm/Group Description	TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1.
Measure Participants	6
TAK-906	1.750
Metabolite (M23)	1.750

7. Secondary Outcome

Title	Period 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906 and M23 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure.

Arm/Group Title	TAK-906 50 mg
Arm/Group Description	TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1.
Measure Participants	6
TAK-906	78.62 (24.5)
Metabolite (M23)	6.185 (37.3)

8. Secondary Outcome

Title	Period 1: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for TAK-906 and M23 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the specified category.

Arm/Group Title	TAK-906 50 mg
Arm/Group Description	TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1.
Measure Participants	6
TAK-906	0.6598 (58.5)
Metabolite (M23)	4.288 (67.7)

9. Secondary Outcome

Title	Period 1: t(1/2)z : Terminal Disposition Phase Half-life for TAK-906 and M23 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the specified category.

Arm/Group Title	TAK-906 50 mg
Arm/Group Description	TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1.
Measure Participants	6
TAK-906	3.892 (73.1)
Metabolite (M23)	1.722 (24.1)

10. Secondary Outcome

Title	Period 1: Vz/F: Apparent Volume of Distribution During the Terminal Elimination Phase for TAK-906 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure.

Arm/Group Title	TAK-906 50 mg
Arm/Group Description	TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [Liters]	3545 (78.3)

11. Secondary Outcome

Title	Period 1: CL/F: Apparent Total Plasma Clearance for TAK-906 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the oral dose of TAK-906 50 mg capsules in Treatment Period 1 were evaluated for this outcome measure.

Arm/Group Title	TAK-906 50 mg
Arm/Group Description	TAK-906 50 mg, capsule, orally, once on Day 1 of Treatment Period 1.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [L/hr]	631.3 (24.2)

12. Secondary Outcome

Title	Period 1: Ceoi: Plasma Total Radioactivity Concentration at the End of Infusion for [14C]-TAK-906
Time Frame	Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 100 μg
Arm/Group Description	[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [nanogramequivalents/milliliter(ng eq/mL)]	3.529 (18.5)

13. Secondary Outcome

Title	Period 1: AUClast: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906
Time Frame	Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 100 μg
Arm/Group Description	[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [ng eq*hr/mL]	2.047 (14.3)

14. Secondary Outcome

Title	Period 1: AUC∞: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906
Time Frame	Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.

Arm/Group Title	[14C]-TAK-906 100 μg
Arm/Group Description	[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.
Measure Participants	3
Geometric Mean (Geometric Coefficient of Variation) [ng eq*hr/mL]	1.976 (14.2)

15. Secondary Outcome

Title	Period 1: t(1/2)z: Terminal Disposition Phase Half-life of Plasma Total Radioactivity Concentration for [14C]-TAK-906
Time Frame	Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.

Arm/Group Title	[14C]-TAK-906 100 μg
Arm/Group Description	[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.
Measure Participants	3
Geometric Mean (Geometric Coefficient of Variation) [hr]	10.847 (137.1)

16. Secondary Outcome

Title	Period 1: Ceoi: Plasma Concentration at the End of Infusion for [14C]-TAK-906
Time Frame	Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 100 μg
Arm/Group Description	[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [picograms (pg)/mL]	3795 (14.1)

17. Secondary Outcome

Title	Period 1: CL: Total Clearance for [14C]-TAK-906
Time Frame	Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 100 μg
Arm/Group Description	[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [L/hr]	57.55 (11.8)

18. Secondary Outcome

Title	Period 1: Vss: Volume of Distribution During the Terminal Disposition Phase for [14C]-TAK-906
Time Frame	Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 100 μg
Arm/Group Description	[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [Liters]	33.04 (14.2)

19. Secondary Outcome

Title	Period 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906
Time Frame	Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 100 μg
Arm/Group Description	[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [pg*hr/mL]	1549 (10.7)

20. Secondary Outcome

Title	Period 1: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for [14C]-TAK-906
Time Frame	Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 100 μg
Arm/Group Description	[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [percentage of AUC]	0.3908 (42.6)

21. Secondary Outcome

Title	Period 1: t(1/2)z: Terminal Disposition Phase Half-life for [14C]-TAK-906
Time Frame	Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the [14C]-TAK-906 μg IV infusion in Treatment Period 1 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 100 μg
Arm/Group Description	[14C]-TAK-906 100 μg (approximately 1 μCi), IV infusion, once on Day 1 of Treatment Period 1, after the TAK-906 oral dose, followed by a Washout Period of 7 days.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [hr]	1.196 (21.2)

22. Secondary Outcome

Title	Period 2: Cmax: Maximum Observed Plasma Concentration for TAK-906 and M23 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
TAK-906	26.81 (31.1)
Metabolite (M23)	1.086 (48.1)

23. Secondary Outcome

Title	Period 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 and M23 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
TAK-906	0.500
Metabolite (M23)	0.999

24. Secondary Outcome

Title	Period 2: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906 and M23 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
TAK-906	46.54 (23.5)
Metabolite (M23)	2.111 (47.7)

25. Secondary Outcome

Title	Period 2: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-906 and M23 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the given category.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
TAK-906	49.40 (18.6)
Metabolite (M23)	2.490 (50.1)

26. Secondary Outcome

Title	Period 2: AUC%Extrap: Percent of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) Extrapolated for TAK-906 and M23 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the given category.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
TAK-906	3.993 (96.7)
Metabolite (M23)	8.013 (50.0)

27. Secondary Outcome

Title	Period 2: t(1/2)z: Terminal Disposition Phase Half-life for TAK-906 and M23 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Number analyzed is the number of participants with data available for analysis for the given category.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
TAK-906	9.993 (29.4)
Metabolite (M23)	1.833 (57.9)

28. Secondary Outcome

Title	Period 2: Vz/F: Apparent Volume of Distribution During the Terminal Elimination Phase for TAK-906 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [Liters]	14430 (29.7)

29. Secondary Outcome

Title	Period 2: CL/F: Apparent Total Plasma Clearance for TAK-906 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [L/hr]	1007 (18.6)

30. Secondary Outcome

Title	Period 2: Cmax: Maximum Observed Plasma Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [ng eq/mL]	39.85 (33.6)

31. Secondary Outcome

Title	Period 2: Tmax: Time to Reach the Maximum Plasma Total Radioactivity Concentration (Cmax) for [14C]-TAK-906 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
Median (Full Range) [hr]	0.758

32. Secondary Outcome

Title	Period 2: AUCt: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Time of the Last Common Time Point t for [14C]-TAK-906 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [ng eq*hr/mL]	109.0 (25.6)

33. Secondary Outcome

Title	Period 2: AUClast: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [ng eq*hr/mL]	135.5 (20.2)

34. Secondary Outcome

Title	Period 2: AUC∞: Area Under the Plasma Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	5
Geometric Mean (Geometric Coefficient of Variation) [ng eq*hr/mL]	144.3 (19.0)

35. Secondary Outcome

Title	Period 2: t(1/2)z: Terminal Disposition Phase Half-life of Plasma Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	5
Geometric Mean (Geometric Coefficient of Variation) [hr]	35.539 (26.2)

36. Secondary Outcome

Title	Period 2: Cmax: Maximum Observed Whole Blood Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [ng eq/mL]	28.41 (26.7)

37. Secondary Outcome

Title	Period 2: Tmax: Time to Reach the Maximum Whole Blood Total Radioactivity Concentration (Cmax) for [14C]-TAK-906 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
Median (Full Range) [hr]	0.504

38. Secondary Outcome

Title	Period 2: AUClast: Area Under the Whole Blood Total Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]-TAK-906 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 144 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [ng eq*hr/mL]	83.17 (13.1)

39. Secondary Outcome

Title	Period 2: AUC∞: Area Under the Whole Blood Total Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-906 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	5
Geometric Mean (Geometric Coefficient of Variation) [ng eq*hr/mL]	87.25 (13.8)

40. Secondary Outcome

Title	Period 2: t(1/2)z: Terminal Disposition Phase Half-life of Whole Blood Total Radioactivity Concentration for [14C]-TAK-906 After Oral Administration
Time Frame	Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Treatment Period 2

Outcome Measure Data

Analysis Population Description

PK Set included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile (e.g., exposure to treatment, availability of measurements and absence of major protocol violations). Participants who received the dose of [14C]-TAK-906 50 mg oral solution in Treatment Period 2 were evaluated for this outcome measure. Overall number analyzed is the number of participants with data available for analysis.

Arm/Group Title	[14C]-TAK-906 50 mg
Arm/Group Description	[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
Measure Participants	5
Geometric Mean (Geometric Coefficient of Variation) [hr]	16.964 (112.1)

Adverse Events

Time Frame	From first dose of study drug up to 30 ± 2 days after last dose of the study drug (Up to approximately 41 days)
Adverse Event Reporting Description	At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment. Safety Population included all participants who received at least one dose of the study drug. As prespecified in the protocol data for adverse events was collected and reported for Treatment Period 1 and Treatment Period 2.
Arm/Group Title	TAK-906 50 mg + [14C]-TAK-906 100 μg		[14C]-TAK-906 50 mg
Arm/Group Description	TAK-906 50 mg, capsule, orally, followed by [14C]-TAK-906 100 μg (approximately 1 μCi), infusion, intravenously, once on Day 1 of Treatment Period 1.		[14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
All Cause Mortality
	TAK-906 50 mg + [14C]-TAK-906 100 μg		[14C]-TAK-906 50 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/6 (0%)		0/6 (0%)
Serious Adverse Events
	TAK-906 50 mg + [14C]-TAK-906 100 μg		[14C]-TAK-906 50 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/6 (0%)		0/6 (0%)
Other (Not Including Serious) Adverse Events
	TAK-906 50 mg + [14C]-TAK-906 100 μg		[14C]-TAK-906 50 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/6 (0%)		2/6 (33.3%)
Gastrointestinal disorders
Abdominal pain upper	0/6 (0%)		1/6 (16.7%)
Diarrhoea	0/6 (0%)		1/6 (16.7%)
Nervous system disorders
Headache	0/6 (0%)		1/6 (16.7%)
Psychiatric disorders
Restlessness	0/6 (0%)		1/6 (16.7%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.